TriSalus Life Sciences (TLSI) Revenue & Revenue Breakdown
TriSalus Life Sciences Revenue Highlights
Latest Revenue (Y)
$45.15M
Latest Revenue (Q)
$8.90M
TriSalus Life Sciences Revenue by Period
TriSalus Life Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $45.15M | 53.41% |
| 2024-12-31 | $29.43M | 58.99% |
| 2023-12-31 | $18.51M | 49.31% |
| 2022-12-31 | $12.40M | 47.58% |
| 2021-12-31 | $8.40M | 100.00% |
| 2020-12-31 | - | - |
TriSalus Life Sciences generated $45.15M in revenue during NA 2025, up 53.41% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
TriSalus Life Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $8.90M | -32.61% |
| 2025-12-31 | $13.21M | 14.17% |
| 2025-09-30 | $11.57M | 3.15% |
| 2025-06-30 | $11.21M | 22.32% |
| 2025-03-31 | $9.17M | 10.97% |
| 2024-12-31 | $8.26M | 12.41% |
| 2024-09-30 | $7.35M | -0.20% |
| 2024-06-30 | $7.36M | 14.05% |
| 2024-03-31 | $6.46M | 12.86% |
| 2023-12-31 | $5.72M | 10.17% |
| 2023-09-30 | $5.19M | 12.60% |
| 2023-06-30 | $4.61M | 54.56% |
| 2023-03-31 | $2.98M | -7.50% |
| 2022-12-31 | $3.23M | -17.77% |
| 2022-09-30 | $3.92M | 36.31% |
| 2022-06-30 | $2.88M | 21.43% |
| 2022-03-31 | $2.37M | -7.64% |
| 2021-12-31 | $2.57M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | - |
TriSalus Life Sciences generated $8.90M in revenue during Q1 2026, up -32.61% compared to the previous quarter, and up 107.72% compared to the same period a year ago.
TriSalus Life Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STIM | Neuronetics | $149.16M | $34.45M |
| OWLT | Owlet | $105.70M | $22.50M |
| LNSR | LENSAR | $58.44M | $13.43M |
| TLSI | TriSalus Life Sciences | $45.15M | $8.90M |
| MXCT | MaxCyte | $33.03M | $9.65M |
| PRE | Prenetics Global | $21.74M | $6.41M |
| PROF | Profound Medical | $16.10M | - |
| NNOX | Nano-X Imaging | $9.90M | $2.55M |
| AVR | Anteris Technologies Global | $1.91M | $494.00K |
| CATX | Perspective Therapeutics | - | - |